Delaware Supreme Court’s Earnout Decision Reinforces Primacy of Contract and Illustrates the Limits of the Implied Covenant

Key Takeaways

• Court rejects implied covenant to rewrite earnout terms
• Parties bound by contract‑defined regulatory approval standards
• Fraud claims barred only with explicit anti‑reliance clause
• Explicit drafting crucial for M&A earnout provisions
• Decision sets precedent for Delaware earnout litigation

Summary

The Delaware Supreme Court issued an en banc opinion in Johnson & Johnson v. Fortis Advisors, affirming and partially reversing a Chancery ruling that awarded former Auris Health shareholders over $1 billion in an earnout dispute. The decision is the first to tackle the recent wave of Delaware earnout cases and underscores the primacy of contract language over the implied covenant of good faith. It holds parties to contract‑specified regulatory‑approval standards and limits fraud claims to situations with clear anti‑reliance language. The ruling highlights the critical need for precise earnout drafting.

Pulse Analysis

Earnout provisions have surged in M&A transactions as buyers and sellers seek to bridge valuation gaps, but the lack of uniform standards has spawned a flurry of litigation in Delaware courts. The Supreme Court’s recent en banc opinion marks a watershed moment, confirming that Delaware judges will not invoke the implied covenant of good faith and fair dealing to reshape the parties’ bargain. By anchoring decisions to the explicit language of the agreement, the court reinforces the state’s reputation for contract certainty, a cornerstone for high‑stakes deals.

The opinion delineates three pivotal principles. First, absent extraordinary circumstances, courts will not rewrite earnout terms based on perceived fairness. Second, when an earnout hinges on regulatory approval, the parties are held to the standards they themselves set, even if those standards reference the buyer’s historical approval practices. Third, extracontractual fraud claims are only precluded when the agreement contains unmistakable anti‑reliance language, not merely an exclusive‑remedy clause. Practitioners must therefore embed clear, objective metrics and explicit anti‑reliance provisions to safeguard against unintended liability.

For dealmakers, the decision sends a clear signal: meticulous drafting is no longer optional but essential. Companies should align earnout triggers with measurable milestones, define regulatory‑approval benchmarks in concrete terms, and incorporate robust anti‑reliance clauses to block post‑closing fraud allegations. As the precedent settles, we can expect a reduction in ambiguous earnout disputes and greater predictability for investors, ultimately fostering smoother transaction execution and more reliable valuation outcomes.